| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Platelet Aggregation Inhibitors | 30 | 2021 | 1671 | 4.28 | Why? |
| Aspirin | 16 | 2021 | 1043 | 3.84 | Why? |
| Platelet Function Tests | 12 | 2021 | 231 | 3.17 | Why? |
| Thrombelastography | 8 | 2021 | 627 | 2.08 | Why? |
| Blood Platelets | 12 | 2021 | 1704 | 1.96 | Why? |
| Purinergic P2Y Receptor Antagonists | 6 | 2018 | 206 | 1.86 | Why? |
| Coronary Artery Disease | 13 | 2020 | 2570 | 1.84 | Why? |
| Platelet Aggregation | 7 | 2021 | 318 | 1.81 | Why? |
| Percutaneous Coronary Intervention | 13 | 2020 | 3646 | 1.64 | Why? |
| Acute Coronary Syndrome | 10 | 2018 | 2107 | 1.57 | Why? |
| Thrombosis | 8 | 2021 | 7504 | 1.12 | Why? |
| Receptors, Purinergic P2Y12 | 4 | 2018 | 42 | 1.10 | Why? |
| Fibrinolytic Agents | 8 | 2020 | 1702 | 1.00 | Why? |
| Prasugrel Hydrochloride | 3 | 2018 | 114 | 0.98 | Why? |
| Thromboxanes | 2 | 2018 | 7 | 0.92 | Why? |
| Cholesterol, LDL | 4 | 2019 | 499 | 0.90 | Why? |
| Myocardial Infarction | 9 | 2020 | 3361 | 0.89 | Why? |
| Blood Coagulation | 3 | 2019 | 2768 | 0.84 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2020 | 1454 | 0.83 | Why? |
| Biomarkers, Pharmacological | 1 | 2021 | 150 | 0.82 | Why? |
| Platelet Activation | 5 | 2019 | 660 | 0.81 | Why? |
| Coronary Thrombosis | 6 | 2020 | 433 | 0.80 | Why? |
| Blood Loss, Surgical | 2 | 2018 | 211 | 0.79 | Why? |
| Postoperative Hemorrhage | 2 | 2018 | 183 | 0.78 | Why? |
| Atrial Fibrillation | 3 | 2019 | 2320 | 0.78 | Why? |
| Rivaroxaban | 3 | 2018 | 467 | 0.78 | Why? |
| Heart-Assist Devices | 2 | 2018 | 812 | 0.77 | Why? |
| Anticholesteremic Agents | 2 | 2019 | 186 | 0.76 | Why? |
| Thrombophilia | 2 | 2021 | 1935 | 0.73 | Why? |
| Drug Monitoring | 4 | 2019 | 1408 | 0.72 | Why? |
| Naproxen | 1 | 2018 | 47 | 0.71 | Why? |
| Drug Resistance | 7 | 2018 | 395 | 0.71 | Why? |
| Anticoagulants | 7 | 2021 | 9563 | 0.67 | Why? |
| Lipoproteins, LDL | 1 | 2017 | 115 | 0.65 | Why? |
| Point-of-Care Testing | 2 | 2021 | 2782 | 0.64 | Why? |
| Lipoproteins, HDL | 1 | 2018 | 154 | 0.63 | Why? |
| Factor Xa Inhibitors | 2 | 2018 | 490 | 0.61 | Why? |
| Drug Therapy, Combination | 9 | 2018 | 7268 | 0.60 | Why? |
| Arterial Pressure | 1 | 2017 | 208 | 0.59 | Why? |
| Cardiovascular Diseases | 7 | 2021 | 11497 | 0.58 | Why? |
| Peripheral Arterial Disease | 2 | 2018 | 471 | 0.58 | Why? |
| Aorta | 1 | 2017 | 355 | 0.55 | Why? |
| Brain Ischemia | 3 | 2020 | 2813 | 0.54 | Why? |
| Cholesterol, HDL | 1 | 2017 | 439 | 0.54 | Why? |
| Coronary Stenosis | 1 | 2017 | 273 | 0.53 | Why? |
| Cardiac Catheterization | 2 | 2017 | 882 | 0.51 | Why? |
| Atherosclerosis | 2 | 2018 | 768 | 0.50 | Why? |
| Lower Extremity | 1 | 2018 | 593 | 0.49 | Why? |
| Ticlopidine | 6 | 2017 | 193 | 0.48 | Why? |
| Stroke | 5 | 2020 | 8839 | 0.48 | Why? |
| Preoperative Care | 2 | 2018 | 1515 | 0.45 | Why? |
| Postmenopause | 1 | 2013 | 160 | 0.44 | Why? |
| von Willebrand Factor | 1 | 2017 | 668 | 0.43 | Why? |
| Gastrointestinal Hemorrhage | 1 | 2017 | 669 | 0.43 | Why? |
| Musculoskeletal Diseases | 1 | 2017 | 646 | 0.40 | Why? |
| Postoperative Complications | 3 | 2018 | 5861 | 0.39 | Why? |
| Stents | 6 | 2020 | 916 | 0.39 | Why? |
| Hemostasis | 3 | 2021 | 811 | 0.39 | Why? |
| Proprotein Convertase 9 | 3 | 2019 | 141 | 0.36 | Why? |
| Hemorrhage | 7 | 2018 | 3013 | 0.35 | Why? |
| Heparin | 1 | 2021 | 2600 | 0.35 | Why? |
| Decision Support Techniques | 3 | 2020 | 903 | 0.33 | Why? |
| Heart Failure | 2 | 2018 | 6638 | 0.31 | Why? |
| Blood Pressure | 1 | 2017 | 2198 | 0.31 | Why? |
| Cardiac Surgical Procedures | 1 | 2018 | 1931 | 0.29 | Why? |
| Predictive Value of Tests | 6 | 2020 | 9537 | 0.28 | Why? |
| Treatment Outcome | 17 | 2021 | 51732 | 0.28 | Why? |
| Thromboembolism | 1 | 2017 | 2101 | 0.28 | Why? |
| Risk Factors | 18 | 2020 | 71621 | 0.27 | Why? |
| Drug Substitution | 2 | 2017 | 385 | 0.27 | Why? |
| Humans | 57 | 2021 | 930598 | 0.26 | Why? |
| Pharmacogenomic Variants | 2 | 2020 | 112 | 0.25 | Why? |
| Fibrin Clot Lysis Time | 1 | 2021 | 35 | 0.24 | Why? |
| Clinical Decision-Making | 5 | 2019 | 3755 | 0.23 | Why? |
| Coronary Disease | 1 | 2007 | 645 | 0.22 | Why? |
| Adenosine Diphosphate | 2 | 2011 | 63 | 0.22 | Why? |
| Drug Administration Schedule | 2 | 2018 | 2324 | 0.22 | Why? |
| Cholesterol | 2 | 2017 | 660 | 0.22 | Why? |
| Verapamil | 1 | 2020 | 46 | 0.21 | Why? |
| Adenosine Monophosphate | 1 | 2018 | 5652 | 0.21 | Why? |
| Prospective Studies | 10 | 2021 | 43301 | 0.21 | Why? |
| Fibrin | 1 | 2021 | 145 | 0.21 | Why? |
| Drug-Eluting Stents | 3 | 2018 | 562 | 0.21 | Why? |
| Biological Availability | 1 | 2021 | 388 | 0.20 | Why? |
| Hyperlipidemias | 1 | 2021 | 290 | 0.19 | Why? |
| Amiodarone | 1 | 2020 | 110 | 0.19 | Why? |
| Role | 1 | 2020 | 266 | 0.19 | Why? |
| Amlodipine | 1 | 2019 | 45 | 0.19 | Why? |
| Matrix Metalloproteinase 13 | 1 | 2018 | 11 | 0.19 | Why? |
| Ion Channels | 1 | 2020 | 167 | 0.19 | Why? |
| Microfilament Proteins | 1 | 2018 | 45 | 0.18 | Why? |
| Thromboxane B2 | 1 | 2018 | 23 | 0.18 | Why? |
| Receptor, PAR-1 | 1 | 2018 | 24 | 0.18 | Why? |
| Ezetimibe | 1 | 2018 | 50 | 0.18 | Why? |
| Matrix Metalloproteinase 1 | 1 | 2018 | 60 | 0.18 | Why? |
| Cross-Over Studies | 2 | 2019 | 867 | 0.17 | Why? |
| Apolipoprotein A-I | 1 | 2018 | 148 | 0.16 | Why? |
| Preliminary Data | 1 | 2019 | 457 | 0.16 | Why? |
| Adenosine | 2 | 2017 | 509 | 0.16 | Why? |
| Middle Aged | 19 | 2021 | 270681 | 0.16 | Why? |
| Endothelial Progenitor Cells | 1 | 2017 | 103 | 0.16 | Why? |
| Risk Assessment | 7 | 2020 | 25439 | 0.16 | Why? |
| Monitoring, Physiologic | 1 | 2007 | 1956 | 0.16 | Why? |
| Atrial Appendage | 1 | 2017 | 120 | 0.15 | Why? |
| Postoperative Period | 1 | 2018 | 651 | 0.15 | Why? |
| African Americans | 2 | 2021 | 3363 | 0.15 | Why? |
| Coronary Artery Bypass | 2 | 2019 | 629 | 0.15 | Why? |
| Aged | 18 | 2021 | 215776 | 0.15 | Why? |
| Fibrinogen | 1 | 2021 | 1048 | 0.15 | Why? |
| Diagnostic Techniques, Cardiovascular | 1 | 2017 | 144 | 0.15 | Why? |
| Female | 22 | 2021 | 380317 | 0.15 | Why? |
| Dabigatran | 1 | 2017 | 204 | 0.14 | Why? |
| Organ Dysfunction Scores | 1 | 2021 | 1475 | 0.14 | Why? |
| Cell Adhesion Molecules | 1 | 2018 | 472 | 0.14 | Why? |
| Carotid Artery Diseases | 1 | 2018 | 251 | 0.14 | Why? |
| Serine Proteinase Inhibitors | 1 | 2019 | 341 | 0.14 | Why? |
| Automation | 1 | 2017 | 429 | 0.14 | Why? |
| Triglycerides | 1 | 2017 | 478 | 0.14 | Why? |
| Thrombin | 1 | 2017 | 325 | 0.14 | Why? |
| Secondary Prevention | 1 | 2019 | 762 | 0.14 | Why? |
| Medication Therapy Management | 1 | 2018 | 312 | 0.14 | Why? |
| Death | 1 | 2017 | 334 | 0.13 | Why? |
| Echocardiography, Transesophageal | 1 | 2017 | 447 | 0.13 | Why? |
| Platelet Membrane Glycoprotein IIb | 1 | 2013 | 2 | 0.13 | Why? |
| Blood Pressure Determination | 1 | 2017 | 450 | 0.13 | Why? |
| Male | 19 | 2021 | 367725 | 0.13 | Why? |
| Antithrombins | 1 | 2017 | 353 | 0.13 | Why? |
| Integrin beta3 | 1 | 2013 | 35 | 0.13 | Why? |
| Follicle Stimulating Hormone | 1 | 2013 | 73 | 0.13 | Why? |
| L-Lactate Dehydrogenase | 1 | 2021 | 1995 | 0.13 | Why? |
| Aortic Diseases | 1 | 2018 | 362 | 0.13 | Why? |
| Time Factors | 6 | 2018 | 31397 | 0.13 | Why? |
| Ventricular Remodeling | 1 | 2017 | 349 | 0.13 | Why? |
| Warfarin | 1 | 2017 | 402 | 0.13 | Why? |
| Non-ST Elevated Myocardial Infarction | 1 | 2018 | 490 | 0.12 | Why? |
| Early Diagnosis | 1 | 2021 | 2443 | 0.12 | Why? |
| Patients | 1 | 2020 | 1167 | 0.12 | Why? |
| Regression Analysis | 2 | 2018 | 2484 | 0.12 | Why? |
| Morbidity | 1 | 2018 | 1426 | 0.12 | Why? |
| Dyslipidemias | 1 | 2019 | 791 | 0.12 | Why? |
| Randomized Controlled Trials as Topic | 4 | 2019 | 10649 | 0.12 | Why? |
| Biomarkers | 5 | 2021 | 23361 | 0.11 | Why? |
| P-Selectin | 1 | 2013 | 224 | 0.11 | Why? |
| Desensitization, Immunologic | 1 | 2017 | 574 | 0.11 | Why? |
| Pyridones | 1 | 2017 | 738 | 0.11 | Why? |
| HIV Infections | 1 | 2017 | 11620 | 0.11 | Why? |
| Lipids | 1 | 2018 | 1079 | 0.11 | Why? |
| Estradiol | 1 | 2013 | 250 | 0.11 | Why? |
| Drug Hypersensitivity | 1 | 2017 | 401 | 0.11 | Why? |
| Contrast Media | 1 | 2017 | 1011 | 0.10 | Why? |
| Drug Interactions | 1 | 2018 | 1653 | 0.10 | Why? |
| HIV | 1 | 2017 | 1116 | 0.10 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.10 | Why? |
| Multivariate Analysis | 2 | 2017 | 5440 | 0.10 | Why? |
| Limit of Detection | 1 | 2017 | 2698 | 0.09 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.09 | Why? |
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2007 | 72 | 0.09 | Why? |
| Coronary Angiography | 1 | 2017 | 2275 | 0.09 | Why? |
| Ventricular Function, Left | 1 | 2017 | 1555 | 0.09 | Why? |
| Angina, Unstable | 1 | 2008 | 110 | 0.08 | Why? |
| Phosphoproteins | 1 | 2018 | 4346 | 0.08 | Why? |
| Diabetes Mellitus | 2 | 2021 | 8207 | 0.08 | Why? |
| Precision Medicine | 1 | 2017 | 1477 | 0.08 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2020 | 3607 | 0.08 | Why? |
| Pilot Projects | 1 | 2019 | 5182 | 0.08 | Why? |
| Pyrazoles | 1 | 2017 | 1791 | 0.08 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 1510 | 0.08 | Why? |
| Risk | 1 | 2018 | 5288 | 0.07 | Why? |
| Internationality | 1 | 2017 | 3297 | 0.07 | Why? |
| Global Health | 2 | 2018 | 13911 | 0.07 | Why? |
| Saliva | 1 | 2020 | 4679 | 0.07 | Why? |
| Chi-Square Distribution | 2 | 2017 | 961 | 0.07 | Why? |
| Emergencies | 1 | 2019 | 4095 | 0.06 | Why? |
| Point-of-Care Systems | 1 | 2017 | 2955 | 0.06 | Why? |
| Consensus | 1 | 2017 | 6345 | 0.06 | Why? |
| Adult | 6 | 2021 | 244371 | 0.05 | Why? |
| Time-to-Treatment | 1 | 2018 | 5883 | 0.05 | Why? |
| Mortality | 1 | 2018 | 7132 | 0.05 | Why? |
| Obesity | 1 | 2021 | 7388 | 0.05 | Why? |
| United States | 4 | 2021 | 46150 | 0.05 | Why? |
| ST Elevation Myocardial Infarction | 1 | 2017 | 3051 | 0.05 | Why? |
| C-Reactive Protein | 2 | 2017 | 7972 | 0.05 | Why? |
| Mice, Knockout, ApoE | 1 | 2018 | 42 | 0.05 | Why? |
| Rosuvastatin Calcium | 1 | 2019 | 89 | 0.05 | Why? |
| Cytochrome P-450 CYP3A | 1 | 2019 | 88 | 0.05 | Why? |
| Matrix Metalloproteinase Inhibitors | 1 | 2018 | 45 | 0.05 | Why? |
| Antibodies, Monoclonal | 1 | 2018 | 8041 | 0.05 | Why? |
| Hydroxamic Acids | 1 | 2018 | 43 | 0.05 | Why? |
| Cell-Penetrating Peptides | 1 | 2018 | 24 | 0.05 | Why? |
| Cytochrome P-450 CYP2C19 | 1 | 2017 | 25 | 0.04 | Why? |
| Prognosis | 1 | 2021 | 32490 | 0.04 | Why? |
| Pharmacogenomic Testing | 1 | 2017 | 115 | 0.04 | Why? |
| Comorbidity | 1 | 2021 | 34796 | 0.04 | Why? |
| Acute Kidney Injury | 1 | 2017 | 5762 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.04 | Why? |
| Sensitivity and Specificity | 1 | 2017 | 22971 | 0.04 | Why? |
| Human Umbilical Vein Endothelial Cells | 1 | 2018 | 286 | 0.04 | Why? |
| Myocardial Revascularization | 1 | 2018 | 267 | 0.04 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.04 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.04 | Why? |
| Antibody Affinity | 1 | 2020 | 1078 | 0.04 | Why? |
| Lipopeptides | 1 | 2018 | 229 | 0.04 | Why? |
| Radiography, Interventional | 1 | 2017 | 158 | 0.04 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.04 | Why? |
| Clinical Trials, Phase II as Topic | 1 | 2018 | 801 | 0.03 | Why? |
| Inflammation | 1 | 2017 | 13255 | 0.03 | Why? |
| Kidney Function Tests | 1 | 2017 | 520 | 0.03 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.03 | Why? |
| Network Meta-Analysis | 1 | 2017 | 426 | 0.03 | Why? |
| Oligopeptides | 1 | 2018 | 576 | 0.03 | Why? |
| Vasodilator Agents | 1 | 2017 | 344 | 0.03 | Why? |
| Administration, Intravenous | 1 | 2017 | 1115 | 0.03 | Why? |
| Plaque, Atherosclerotic | 1 | 2018 | 423 | 0.03 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.03 | Why? |
| Animals | 2 | 2020 | 78931 | 0.03 | Why? |
| Severity of Illness Index | 2 | 2020 | 48226 | 0.03 | Why? |
| Patient Selection | 2 | 2018 | 4560 | 0.03 | Why? |
| Down-Regulation | 1 | 2019 | 1416 | 0.03 | Why? |
| Germany | 2 | 2018 | 9196 | 0.03 | Why? |
| Poland | 1 | 2020 | 2368 | 0.03 | Why? |
| Purinergic P2 Receptor Antagonists | 1 | 2010 | 7 | 0.03 | Why? |
| Aging | 1 | 2008 | 3581 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2018 | 2437 | 0.03 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.03 | Why? |
| Linear Models | 1 | 2017 | 1914 | 0.03 | Why? |
| Administration, Oral | 1 | 2017 | 2340 | 0.03 | Why? |
| Needs Assessment | 1 | 2020 | 2352 | 0.03 | Why? |
| Pandemics | 4 | 2020 | 389249 | 0.02 | Why? |
| Retrospective Studies | 2 | 2018 | 105322 | 0.02 | Why? |
| Registries | 2 | 2018 | 12327 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2020 | 51949 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| Medication Adherence | 1 | 2017 | 1270 | 0.02 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2018 | 2483 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2018 | 5542 | 0.02 | Why? |
| World Health Organization | 1 | 2020 | 4213 | 0.02 | Why? |
| Double-Blind Method | 1 | 2018 | 5988 | 0.02 | Why? |
| Angioplasty, Balloon, Coronary | 1 | 2010 | 365 | 0.02 | Why? |
| Antihypertensive Agents | 1 | 2019 | 1962 | 0.02 | Why? |
| Republic of Korea | 1 | 2019 | 5858 | 0.02 | Why? |
| Inflammation Mediators | 1 | 2017 | 2654 | 0.02 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Europe | 1 | 2020 | 12702 | 0.02 | Why? |
| Antigens, Viral | 1 | 2020 | 6298 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.02 | Why? |
| Echocardiography | 1 | 2017 | 3661 | 0.02 | Why? |
| Cell Line | 1 | 2018 | 12040 | 0.01 | Why? |
| Case-Control Studies | 1 | 2021 | 17671 | 0.01 | Why? |
| Logistic Models | 1 | 2017 | 9089 | 0.01 | Why? |
| Viral Proteins | 1 | 2020 | 7370 | 0.01 | Why? |
| Signal Transduction | 1 | 2018 | 7207 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2018 | 10998 | 0.01 | Why? |
| Disease Progression | 1 | 2018 | 13580 | 0.01 | Why? |
| ROC Curve | 1 | 2010 | 6024 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2020 | 21571 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.01 | Why? |
| Age Factors | 1 | 2008 | 21039 | 0.00 | Why? |
| Cohort Studies | 1 | 2008 | 36005 | 0.00 | Why? |